

N/Re. : 50106

183

180

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

División de Nuevas Creaciones

E.

S.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
Rad: 00-001000-00011-0000 Fec: 2008-04-25 17:22:10
Dep. 2020 NUECREACIONES
Tit: 2 PATENTES Evt 1 REGDEPOSITO
Act 444 RESPUESTAREQUE Folia: 37

9998
RE: EXPEDIENTE No. 00091958

Solicitud de Patente

Solicitante: AVENTIS CROPSCIENCE S.A

Yo, LUIS PATIÑO LEYVA, vecino de Bogotá, D. C., portador de la tarjeta profesional No. 2698, obrando como apoderado en la solicitud de patente de la referencia, doy respuesta al oficio No. 1033, notificado por fijación en lista de Febrero 2 de 2006, en los siguientes términos:

1. CLARIDAD DE LA SOLICITUD:

Con el animo de superar la objeción respecto a la claridad de la solicitud, me permito modificar el titulo de la invención por el siguiente:

**COMPUESTO PARA EL CONTROL DE ARTROPODOS EN ANIMALES Y LA
COMPOSICIÓN NO- EMÉTICA QUE LO COMPRENDE**

De otra parte no entendemos las objeciones relativas a la utilización de términos subjetivos, pues son la forma de expresar en castellano las condiciones de los compuestos y no son apreciaciones subjetivas. No debe olvidar el examinador que en sentencia de Marzo 9 de 2006 del Consejo de Estado, correspondiente al expediente No. 97-062569 de la Superintendencia de Industria y Comercio, tanto el Tribunal Andino de Justicia como el Consejo de Estado exigen que los estudios de patentabilidad sean claros y precisos y no pueden estar sujetos o fundamentados en apreciaciones, estas si, subjetivas del examinador de patentes, pues le restan al interesado capacidad para defenderse.

124
181
OTO!

Adicionalmente, es importante señalar que cuando en la memoria descriptiva y en las reivindicaciones se usa el adverbio sustancialmente, este adverbio le permitirá a una persona capacitada (técnico medio) interpretar y ejecutar la invención. Hay que tener en cuenta que en el Artículo 28 de la Decisión 486 de 2000, que se cita como sustento de la objeción, usa adverbios semejantes a sustancialmente: "suficientemente", el hecho de usar este adverbio no lo hace inteligible y permite entender la norma.

no es claro!
¿Qué? ¿lo?
"Claridad"

2. Teniendo en cuenta las objeciones relativas al nivel inventivo y a las excepciones de las que trata el Artículo 20 de la Decisión 486 de 2000, me permito presentar nuevo pliego reivindicatorio, el cual reemplaza al inicialmente presentado, el cual es aceptable dado que éste no implica una ampliación de la solicitud originalmente presentada conforme al Artículo 34 de la Decisión, el cual establece: "El solicitante de una patente podrá pedir que se modifique la solicitud en cualquier momento del trámite. La modificación no podrá implicar una ampliación de la protección que correspondería a la divulgación contenida en la solicitud inicial (...)".

Las reivindicaciones aquí propuestas pertenecen a la solicitud divisional No. 09/727,684, patente concedida No. 6.992.099 de Enero 31 de 2006, circunstancia que debe ser tomada en cuenta al tenor Artículo 46: "la oficina nacional competente podrá reconocer los resultados de los exámenes referidos en el literal b) como suficientes para acreditar el cumplimiento de las condiciones de patentabilidad de la invención".

El nuevo capítulo reivindicatorio cumple con el requisito de unidad de la invención de acuerdo con el Artículo 25, puesto que todas las combinaciones inventivas se derivan de un único concepto inventivo común.

Anexo al presente memorial nuevo capítulo reivindicatorio y copia de la patente No. 6.992.099B2.

De la señora jefe,



LUIS PATINO LEYVA

C.C No. 2.960.616 de Bogotá


T.P No. 2698

185
182

REIVINDICACIONES

Lo que se reivindica es:

1. Un compuesto que tiene la fórmula (II):



NO SE puede leer. Está borrado.

? No es clara esta fórmula!

donde:

R₂₁ es ciano, C(=S)NH₂, C(=NOH)NH₂ o C(=NN₂H)NH₂;

R₂₂ es S(O)_mR₂₃;

R₂₃ es alquil o haloalquil;

R₂₄ es OH, HC(O)O—, R₂₅OC(O)O—, R₂₅R₂₅N-C(O)—O— o R₂₅S(O)_nC(O)—;

R₂₅ es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, heteril opcionalmente sustituido, arilalquil opcionalmente sustituido, heterilalquil opcionalmente sustituido, C₂-C₆ alquenil o C₂-C₆ alquini;

X cuantos grupos?

En qué momento puede estar sustituido?

o dos grupos R_{25} forman conjuntamente con el nitrógeno al cual están unidos un anillo de 3 a 7 miembros el cual tiene opcionalmente uno o más heteroátomos adicionales seleccionados del grupo que consiste de nitrógeno, oxígeno y azufre;

X es $C-R_{32}$;

R_{31} y R_{32} se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C_1-C_3 alquil y NO_2 ;

R_{33} se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, $-S(O)$, CF_3 y SF_5 ;

r se selecciona a partir del grupo que consiste de 0, 1 y 2; y cuando R_{21} es ciano, m se selecciona a partir del grupo que consiste de 1 y 2, o

cuando R_{21} no es ciano, m se selecciona a partir del grupo que consiste de 0, 1 y 2;

o su sal veterinariamente acceptable;

teniendo en cuenta que cuando R_{21} es ciano, entonces R_{24} , no es $R_{23}R_{25}-N-C(O)-$.

2. Un compuesto de acuerdo con la reivindicación 1, donde:

R_{21} es ciano,

R_{22} es $S(O)_m R_{23}$;

R_{23} es haloalquil;

R_{24} es OH;

X es $C-R_{32}$,

R_{31} y R_{32} se seleccionan independientemente a partir de halógeno;

R_{33} se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, $-S(O)$, CF_3 y SF_5 ;

r se selecciona a partir del grupo que consiste 0, 1 y 2; y

184


? Esta palabra no es.

m se selecciona a partir del grupo que consiste de 1 y 2.

188
185

3. Un compuesto de acuerdo con la reivindicación 2, donde R₂₃ es CF₃.
4. El compuesto de acuerdo con la reivindicación 2, el cual es 1-(2,6- dicloro-4-trifluorometilfenil)-3-ciano-4-trifluorometilsulfinil-5-hidroxipirazolo. *- pirazol.*
5. El compuesto de acuerdo con la reivindicación 2, el cual es 1-(2,6- dicloro-4-trifluorometilfenil)-3-ciano-4-trifluorometilsulfonil-5-hidroxipirazolo.
6. Una composición que comprende una cantidad parasíticamente efectiva, sustancialmente no-emética de un compuesto de la fórmula (II) como se definió en la reivindicación 1, o su sal apta veterinariamente, y un portador veterinariamente apto. *? mal traducido.*
7. Una composición que comprende una cantidad parasíticamente efectiva, sustancialmente non-emética de un compuesto como se definió en la reivindicación 2, y su sal veterinariamente aceptable.
8. Una composición que comprende una cantidad parasíticamente efectiva, sustancialmente non-emética de un compuesto como se definió en la reivindicación 3, y su sal veterinariamente aceptable.
9. Una composición que comprende una cantidad parasíticamente efectiva, sustancialmente non-emética de un compuesto como se definió en la reivindicación 4, y su sal veterinariamente aceptable.

10. Una composición que comprende una cantidad parasíticamente efectiva, sustancialmente non-emética de un compuesto como se definió en la reivindicación 5, y su sal veterinariamente aceptable.
11. Un compuesto que tiene la fórmula (II);



donde:

R_{21} es ciano, $C(=S)NH_2$, $C(=NOH)NH_2$ o $C(=NN_2H)NH_2$;

R_{22} es $S(O)_m R_{23}$;

R_{23} es alquil o haloalquil;

R_{24} es OH , $HC(O)O-$, $R_{25}OC(O)O-$, $R_{25}R_{25}N-C(O)-O-$ o $R_{25}S(O)_n C(O)-$;

R_{25} es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C_2-C_6 alquenil o C_2-C_6 alquinil;

o dos grupos R_{25} forman conjuntamente con el nitrógeno al cual están unidos un anillo de 3 a 7 miembros el cual tiene opcionalmente uno o más heteroátomos adicionales seleccionados del grupo que consiste de nitrógeno, oxígeno y azufre;

X es $C-R_{32}$;

R_{31} y R_{32} se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C_1-C_3 alquil y NO_2 ;


R_{33} se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, $-S(O)$, CF_3 y SF_5 ;

m se selecciona a partir del grupo que consiste de 1 y 2; y

r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable:

teniendo en cuenta que cuando R_{21} es ciano, entonces R_{24} no es $R_{25}R_{25}-N-C(O)-$.

12. Un compuesto que tiene la fórmula (II);



donde:

R_{21} es ciano;

R_{22} es $S(O)_m R_{23}$;

R_{23} es alquil o haloalquil;

R_{24} es OH, $HC(O)O-$, $R_{25}OC(O)O-$, $R_{25}R_{25}N-C(O)-O-$ o $R_{25}S(O)_n C(O)-$;

aca halogeno, cuantos el alquilo?

181
188

R_{25} es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C_2-C_6 alquenil o C_2-C_6 alquinil;

o dos grupos R_{25} forman conjuntamente con el nitrógeno al cual están unidos un anillo de 3 a 7 miembros el cual tiene opcionalmente uno o más heteroátomos adicionales seleccionados a partir del grupo que consiste de nitrógeno, oxígeno y azufre;

X es $C-R_{32}$;

R_{31} y R_{32} se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C_1-C_3 alquil y NO_2 ;

R_{33} se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, $-S(O)$, CF_3 y SF_5 ;

m se selecciona a partir del grupo que consiste de 1 y 2; y


r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable.

y cuando R_{21} es ciano, m se selecciona a partir del grupo que consiste de 1 y 2, o cuando R_{21} no es ciano, m se selecciona a partir del grupo que consiste de 0, 1 y 2;

o su sal veterinariamente aceptable;

teniendo en cuenta que cuando R_{21} es ciano, entonces R_{24} , no es $R_{23}R_{25}-N-C(O)-$.

13. Un compuesto que tiene la fórmula (II):



donde:

R_{21} es $C(=S)NH_2$, $(=NOH)NH_2$ o $C(=NH_2)NH_2$;

R_{22} es $S(O)_m R_{23}$;

R_{23} es alquil o haloalquil;

R_{24} es OH , $HC(O)O-$, $R_{25}OC(O)O-$, $R_{25}R_{25}N-C(O)-O-$ o $R_{25}S(O)_m C(O)-$;

R_{25} es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C_2-C_6 alquenil o C_2-C_6 alquinil;

o dos grupos R_{25} forman conjuntamente con el nitrógeno al cual están unidos un anillo de 3 a 7 miembros el cual tiene opcionalmente uno o más heteroátomos adicionales seleccionados a partir del grupo que consiste de nitrógeno, oxígeno y azufre;

X es $C-R_{32}$;

R_{31} y R_{32} se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN , C_1-C_3 alquil y NO_2 ;

182
189


183
190

R₃₃ se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, —S(O), CF₃ y SF₅;

m se selecciona a partir del grupo que consiste de 1 y 2; y

r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable.

14. Una composición que comprende una cantidad parasíticamente efectiva, sustancialmente no-emética de un compuesto de fórmula (II) como se definió en la reivindicación 11, o su sal veterinariamente aceptable y su portador veterinariamente aceptable.
15. Una composición que comprende una cantidad parasíticamente efectiva, sustancialmente no-emética de un compuesto como se definió en la reivindicación 12, y su portador veterinariamente aceptable.
16. Una composición que comprende una cantidad parasíticamente efectiva, sustancialmente no-emética de un compuesto como se definió en la reivindicación 13, y su portador veterinariamente aceptable.
17. Un compuesto de acuerdo con la reivindicación 1, que tiene la fórmula (II):



donde:

R₂₁ es ciano; C(=S)NH₂, (=NOH)NH₂ o C(=NH₂)NH₂ ;

R₂₂ es S(O)_m R₂₃;

R₂₃ es alquil o haloalquil;

R₂₄ es OH, HC(O)O—, R₂₅OC(O)O—, R₂₅R₂₅N-C(O) —O— o R₂₅S(O)_nC(O)—;

R₂₅ es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C₂-C₆ alquenil o C₂-C₆ alquinil;

X es C—R₃₂;

R₃₁ y R₃₂ se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C₁-C₃ alquil y NO₂;

R₃₃ se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, —S(O), CF₃ y SF₅;

r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable y cuando R₂₁ es ciano, m se selecciona a partir del grupo que consiste de 1 y 2, o


cuando R₂₁ no es ciano, m se selecciona a partir del grupo que consiste de 0, 1 y 2;

o su sal veterinariamente aceptable;

teniendo en cuenta que cuando R₂₁ es ciano, entonces R₂₄, no es R₂₅R₂₅ —N—C(O)—.

18. Un compuesto de acuerdo con la reivindicación 11, que tiene la fórmula (II):

312
191



donde:

R_{21} es ciano, $C(=S)NH_2$, $(=NOH)NH_2$ o $C(=NH_2)NH_2$;

R_{22} es $S(O)_m R_{23}$;

R_{23} es alquil o haloalquil;

R_{24} es OH , $HC(O)O-$, $R_{25}OC(O)O-$, $R_{25}R_{25}N-C(O)-O-$ o $R_{25}S(O)_n C(O)-$;

R_{25} es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C_2-C_6 alquenil o C_2-C_6 alquinil;

X es $C-R_{32}$;

R_{31} y R_{32} se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN , C_1-C_3 alquil y NO_2 ;


R_{33} se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, $-S(O)$, CF_3 y SF_5 ;

m se selecciona a partir del grupo que consiste de 1 y 2; y

r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable;

teniendo en cuenta que cuando R_{21} es ciano, entonces R_{24} no es $R_{25}R_{25}-N-C(O)-(O)-$.

19. Un compuesto de acuerdo con la reivindicación 12, que tiene la fórmula (II):



donde:

R_{21} es ciano;

R_{22} es $S(O)_m R_{23}$;

R_{23} es alquil o haloalquil;

R_{24} es OH, $HC(O)O-$, $R_{25}OC(O)O-$, $R_{25}R_{25}N-C(O)-O-$ o $R_{25}S(O)_n C(O)-$;

R_{25} es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetariil opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C_2-C_6 alquenil o C_2-C_6 alquinil;

X es $C-R_{32}$;


R_{31} y R_{32} se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C_1-C_3 alquil y NO_2 ;

R_{33} se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, $-S(O)$, CF_3 y SF_5 ;

m se selecciona a partir del grupo que consiste de 1 o 2; y r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable.

194

20. Un compuesto de acuerdo con la reivindicación 13, que tiene la fórmula (II):



donde:

R₂₁ es C(=S)NH₂, (=NOH)NH₂ o C(=NH₂)NH₂;

R₂₂ es S(O)_mR₂₃;

R₂₃ es alquil o haloalquil;

R₂₄ es OH, HC(O)O—, R₂₅OC(O)O—, R₂₅R₂₅N-C(O) —O— o R₂₅S(O)_nC(O)—;

R₂₅ es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C₂-C₆ alquenil o C₂-C₆ alquínil;

X es C—R₃₂;

R₃₁ y R₃₂ se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C₁-C₃ alquil y NO₂;


R₃₃ se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, —S(O), CF₃ y SF₅;

m se selecciona a partir del grupo que consiste de 1 y 2; y

r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable.

198
195

21. Un compuesto de acuerdo con la reivindicación 1, que tiene la fórmula (II):



donde:

R₂₁ es ciano, C(=S)NH₂, (=NOH)NH₂ o C(=NH₂)NH₂ ;

R₂₂ es S(O)_mR₂₃;

R₂₃ es alquil o haloalquil;

R₂₄ es OH;

R₂₅ es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C₂-C₆ alquenil o C₂-C₆ alquinil;

X es C—R₃₂;


R₃₁ y R₃₂ se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C₁-C₃ alquil y NO₂;

R₃₃ se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, —S(O), CF₃ y SF₅;

r se selecciona a partir del grupo que consiste de 0, 1 y 2; y cuando R_{21} es ciano, m se selecciona a partir del grupo que consiste de 1 o 2, o

cuando R_{21} no es ciano, m se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable.

22. Un compuesto de acuerdo con la reivindicación 11, que tiene la fórmula (II):



donde:

R_{21} es ciano, $C(=S)NH_2$, $(=NOH)NH_2$ o $C(=NH_2)NH_2$;

R_{22} es $S(O)_m R_{23}$;

R_{23} es alquil o haloalquil;

R_{24} es OH;

R_{25} es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C_2-C_6 alquenil o C_2-C_6 alquinil;

X es $C-R_{32}$;


R_{31} y R_{32} se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C_1-C_3 alquil y NO_2 ;

R_{33} se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, $-S(O)$, CF_3 y SF_5 ;

m se selecciona a partir del grupo que consiste 1 y 2; y

r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable.

23. Un compuesto de acuerdo con la reivindicación 12, que tiene la fórmula (II):



donde:

R₂₁ es ciano;

R₂₂ es S(O)_mR₂₃;

R₂₃ es alquil o haloalquil;

R₂₄ es OH;

R₂₅ es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalcoxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C₂-C₆ alquenil o C₂-C₆ alquinil;

X es C—R₃₂;

R₃₁ y R₃₂ se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C₁-C₃ alquil y NO₂;


R₃₃ se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, —S(O), CF₃ y SF₅;

m se selecciona a partir del grupo que consiste 1 y 2; y

r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable.

198
201

24. Un compuesto de acuerdo con la reivindicación 13, que tiene la fórmula (II):



donde:

R₂₁ es C(=S)NH₂, (=NOH)NH₂ o C(=NH₂)NH₂;

R₂₂ es S(O)_mR₂₃;

R₂₃ es alquil o haloalquil;

R₂₄ es OH;

R₂₅ es alquil, haloalquil, cicloalquil, halocicloalquil, alcoxialquil, haloalc oxialquil, adamantil, aminoalquil, alquilaminoalquil, dialquilaminoalquil, haloalquilaminoalquil, di(haloalquil)-aminoalquil, aril opcionalmente sustituido, hetaril opcionalmente sustituido, arilalquil opcionalmente sustituido, hetarilalquil opcionalmente sustituido, C₂-C₆ alquenil o C₂-C₆ alquinil;

X es C—R₃₂;

R₃₁ y R₃₂ se seleccionan independientemente a partir del grupo que consiste de halógeno, hidrógeno, CN, C₁-C₃ alquil y NO₂;

R₃₃ se selecciona a partir del grupo que consiste de halógeno, haloalquil, haloalcoxi, —S(O), CF₃ y SF₅;

m se selecciona a partir del grupo que consiste 1 y 2; y

r se selecciona a partir del grupo que consiste de 0, 1 y 2; o su sal veterinariamente aceptable.

- 25. Una composición que comprende una cantidad parasitidamente efectiva, sustancialmente no-emética, de un compuesto de la fórmula (II) como se definió en la reivindicación 17, de su sal veterinariamente aceptable, y su portador veterinariamente aceptable.**
- 26. Una composición que comprende una cantidad parasitidamente efectiva, sustancialmente no-emética de un compuesto como se definió en la reivindicación 18, y su portador veterinariamente aceptable.**
- 27. Una composición que comprende una cantidad parasitidamente efectiva, sustancialmente no-emética de un compuesto como se definió en la reivindicación 19, y su portador veterinariamente aceptable.**
- 28. Una composición que comprende una cantidad parasitidamente efectiva, sustancialmente no-emética de un compuesto como se definió en la reivindicación 20, y su portador veterinariamente aceptable.**
- 29. Una composición que comprende una cantidad parasitidamente efectiva, sustancialmente no-emética de un compuesto como se definió en la reivindicación 21, o su sal veterinariamente aceptable y su portador veterinariamente aceptable.**

35
207
199

30. Una composición que comprende una cantidad parasitidamente efectiva, sustancialmente no-emética de un compuesto como se definió en la reivindicación 22, y su portador veterinariamente aceptable.
31. Una composición que comprende una cantidad parasitidamente efectiva, sustancialmente no-emética de un compuesto como se definió en la reivindicación 22, o su sal veterinariamente aceptable y su portador veterinariamente aceptable.
32. Una composición que comprende una cantidad parasitidamente efectiva, sustancialmente no-emética de un compuesto como se definió en la reivindicación 24, o su sal veterinariamente aceptable y su portador veterinariamente aceptable.

203
200



US006992099B2

(12) **United States Patent**
Huber et al.

(10) Patent No.: **US 6,992,099 B2**
(45) Date of Patent: **Jan. 31, 2006**

(54) **CONTROL OF ARTHROPODS IN ANIMALS**

(75) Inventors: Scot Kevin Huber, Raleigh, NC (US);
David Teh-Wel Chou, Raleigh, NC
(US); Stefan Schnatterer, Hattenheim
(DE); Henricus Maria Martinus
Bastlaans, Raleigh, NC (US)

(73) Assignee: Aventis Cropscience S.A., Lyons (FR)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: 10/406,491

(22) Filed: Apr. 4, 2003

(65) Prior Publication Data
US 2003/0176466 A1 Sep. 18, 2003

Related U.S. Application Data

(62) Division of application No. 09/727,684, filed on Dec.
4, 2000, now Pat. No. 6,569,886.

(60) Provisional application No. 60/168,658, filed on Dec.
2, 1999.

(51) Int. Cl.
A61K 31/4152 (2006.01)
C07D 231/16 (2006.01)
C07D 231/18 (2006.01)

(52) U.S. Cl. 514/407; 548/366.1; 548/366.7;
514/407

(58) Field of Classification Search 548/366.1,
548/366.7; 514/407
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,770,692 A 9/1988 Stetter et al.
4,918,085 A * 4/1990 D'Silva et al. 514/407
5,047,550 A * 9/1991 D'Silva 548/366.7
5,079,370 A * 1/1992 D'Silva et al. 548/366.7

5,082,945 A 1/1992 Weisselman et al.
5,175,176 A 12/1992 Sasse et al.
5,232,940 A 8/1993 Hatten et al.
5,283,337 A 2/1994 Weisselman et al.

FOREIGN PATENT DOCUMENTS

AU	720952 B	4/1997
AU	199855541 B2	6/1998
EP	0249033 A	12/1987
EP	0257296 A	3/1988
EP	0295117	12/1988
EP	0385809	9/1990
EP	0469357 A	2/1992
EP	0846686 A1	6/1998
JP	2000169453 A	6/2000
WO	94/21606	9/1994
WO	97/07102	2/1997
WO	97/12521 A	4/1997
WO	97/28126	8/1997
WO	98/24767	6/1998
WO	98/28277	7/1998
WO	98/28278	7/1998
WO	98/28279	7/1998

OTHER PUBLICATIONS

DATABASE Accession No. 133:30728, XP 002172128,
Abstract of JP 2000 169453, published Jun. 20, 2000.
Clavel et al, Reactions of Bromotrifluoromethane and
Related Halides, Part 12, Transformation of Disulfides into
Perfluoroalkyl Sulfides in the Presence of Sulfoxylate Anion
Radical Precursors, *J. Chem. Soc. Perkin Trans. 1*, pp.
3371-3375 (1992), published by Chemical Society, London,
Great Britain.

* cited by examiner

Primary Examiner—Joseph K. McKane

Assistant Examiner—Janet L. Coppins

(74) Attorney, Agent, or Firm—Buchanan Ingersoll PC

(57) **ABSTRACT**

A method of controlling parasites in or on an animal
comprising administering to the animal a parasitically
effective, substantially non-emetic 1-arylpyrazole.

32 Claims, No Drawings

CONTROL OF ARTHROPODS IN ANIMALS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 09/727,684, filed Dec. 4, 2000, Now U.S. Pat. No. 6,569,886, which claims the benefit of U.S. Provisional Application No. 60/168,658, filed Dec. 2, 1999, both of which are incorporated by reference herein in their entireties and relied upon.

The present invention relates to a method of control of parasites in animals, compositions comprising a compound effective for the said control and compounds effective against parasites.

It is generally a goal of agronomists and veterinarians to possess sufficient means to control pests, particularly arthropods, when they attempt to invade or attack mammals, particularly domestic animals and/or livestock. A classical method of controlling such pests has been the use of topical and/or systemic pesticides on or in the domestic animal which is being attacked. Generally effective treatments include the oral administration of insect growth regulators, such as hufesuron, or antihelminth compounds such as an ivermectin or an avermectin, or the topical application of the insecticide fipronil. It is advantageous to apply pesticides to animals in oral form so as to prevent the possible contamination of humans or the surrounding environment.

It is an object of the present invention to provide new pesticides which may be used in domestic animals.


Another object of the invention is to provide safer pesticides for domestic animals.

Another object of the invention is to provide new pesticides for domestic animals that may be used in lower doses than existing pesticides.

These objects are met in whole or in part by the present invention.


U.S. Pat. No. 5,079,370, EP-A 0846686, WO 98/24769 and WO 97/28126 disclose the use of arylpyrazoles as parasitocidal agents. However, these references are completely silent on the problem that antiparasitocidal agents often elicit emesis in the animal to be protected or cured from the parasites.

The present invention provides a method of controlling parasites in or on an animal comprising administering, preferably orally, to the animal a parasitocidally effective, substantially non-emetic amount of a 1-arylpyrazole of formula (I):



wherein:

R₂₀₁ is cyano, C(O)alkyl, C(S)NH₂, C(NH)OR₂₀₃, C(NH)SR₂₀₃, alkyl, C(=NOH)NH₂, C(=NNH₂)NH₂, C(O)NH₂, C(O)NHR₂₀₃, C(O)NR₂₀₃R₂₀₄, haloalkyl or heterocyclyl from the group:



optionally substituted by R₂₀₃;

R₂₀₂ is S(O)_nR₂₀₃, C₂-C₆ alkenyl, C₂-C₆ haloalkenyl, cycloalkyl, halocycloalkyl, cycloalkyl-alkyl, C₂-C₆ alkynyl, nitro or imidazol-2-yl optionally substituted by alkyl, alkoxy, haloalkyl, halogen, cyano and/or nitro;

R₂₀₃ is alkyl or haloalkyl;

R₂₀₄ is —OH, R₂₀₃O—, HC(O)O—, R₂₀₃C(O)O—, R₂₀₃OC(O)O—, NH₂C(O)O—, R₂₀₃NHC(O)O—, R₂₀₃R₂₀₄NC(O)O—, R₂₀₃S(O)_nC(O)O—, R₂₀₃SO₂O—, aryl-SO₂O—, (C₁-C₂)-oxacycloalkyloxy, R₂₀₃R₂₀₄N—C(NR₂₀₃)—O—, R₂₀₃R₂₀₄N—C(NH)—O—, R₂₀₃NH—C(NR₂₀₃)—O—, R₂₀₃NH—C(NH)—O—, R₂₀₃N=CH—O—, R₂₀₃N=C(R₂₀₄)—O—, R₂₀₃NH—C(S)—O—, R₂₀₃R₂₀₄N—C(S)—O—;

R₂₀₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted, C₂-C₆ alkenyl, C₂-C₆ alkynyl;

R₂₀₆ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted;

or R₂₀₅ and R₂₀₆ may form together with the nitrogen to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;

X₁ is selected from nitrogen and C—R₂₁₂;

R₂₁₂, R₂₁₃ are independently selected from halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂;

R₂₁₃ is selected from halogen, haloalkyl, haloalkoxy, —S(O)_nCF₃, and —SF₃ or forms a ring with R₂₁₄;

R₂₁₄ is hydrogen or may constitute together with R₂₁₃ a group of OCF₂O, CF₂OCF₂, CF₂OCF₂O and CF₂CF₂O, which forms together with the carbons they are attached to a five to six membered ring; and

h, k and n are independently selected from 0, 1, and 2;

(I) and veterinarily acceptable salts thereof.

By the term "veterinarily acceptable salts" is meant salts the anions of which are known and accepted in the art for the formation of salts for veterinary use. Suitable acid addition salts, e.g. formed by compounds of formula (I) containing a basic nitrogen atom, e.g. an amino group, include salts with inorganic acids, for example hydrochlorides, sulphates, phosphates and nitrates and salts with organic acids for example acetic acid.

When R₂₀₄ is OH the pyrazole structure can also be exhibited by its tautomeric form as pyrazolon structure.

Unless otherwise specified, alkyl and alkoxy groups are straight chain or branched and are generally lower alkyl and alkoxy groups, that is having from one to six carbon atoms,

preferably from one to four carbon atoms. Generally, the haloalkyl, haloalkoxy and haloalkylamino groups have from one to four carbon atoms. Halogen means F, Cl, Br, and I, preferably F and Cl. The haloalkyl and haloalkoxy and haloalkylamino groups can bear one or more halogen atoms; preferred groups of this type include $-\text{CF}_3$ and $-\text{OCF}_3$. Cycloalkyl groups generally have from 3 to 6 carbon atoms, preferably from 3 to 5 carbon atoms and may be substituted by one or more halogen atoms. Preferably in compounds of formula (I), alkyl groups are generally substituted by from one to five halogen atoms, preferably from one to three halogen atoms. Chlorine and fluorine atoms are preferred.

In compounds of formula (I) the following examples of radicals are provided:

An example of cycloalkylalkyl is cyclopropylmethyl; an example of cycloalkoxy is cyclopropyloxy; and an example of alkoxyalkyl is CH_3OCH_2- .

Generally, in dialkylamino or di(haloalkyl)amino radicals, the alkyl and haloalkyl groups on nitrogen may be chosen independently of one another.

Generally, the term "aryl" means a carbocyclic aromatic radical having preferably 6 to 14, in particular 6 to 12, carbon atoms, for example phenyl, naphthyl or biphenyl, preferably phenyl;

the term "heterocyclyl" preferably means a hetaryl or heteroaliphatic ring system, "hetaryl" preferably being understood as meaning an aryl radical in which at least one CH group is replaced by N and/or at least two adjacent CH groups are replaced by S, NH or O, for example a radical of thiophene, furan, pyrrole, thiazole, oxazole, imidazole, isothiazole, isoxazole, pyrazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,3,4-triazole, 1,2,4-oxadiazole, 1,2,4-thiadiazole, 1,2,4-triazole, 1,2,3-triazole, 1,2,3,4-tetrazole, benzo[b]thiophene, benzo[b]furan, indole, benzo[c]thiophene, benzo[c]furan, isoindole, benzoxazole, benzothiazole, benzimidazole, benzisoxazole, benzisothiazole, benzopyrazole, benzothiadiazole, benzotriazole, dibenzofuran, dibenzothiophene, carbazole, pyridine, pyrazine, pyrimidine, pyridazine, 1,3,5-triazine, 1,2,4-triazine, 1,2,4,5-triazine, quinoxaline, isoquinoxaline, quinoxaline, cinnoline, 1,8-naphthyridine, 1,5-naphthyridine, 1,6-naphthyridine, 1,7-naphthyridine, phthalazine, pyridopyrimidine, purine, pteridine or 4H-quinolizine;

and the term "heteroaliphatic ring system" preferably means a (C_2-C_6) cycloalkyl radical in which at least one carbon unit is replaced by O, S or a group NR' and R' is hydrogen, (C_1-C_4) alkyl, (C_1-C_4) alkenyl, (C_1-C_4) alkoxycarbonyl, (C_1-C_4) alkylsulfonyl, (C_1-C_4) alkoxy or aryl.

The substituents with which the various aliphatic, cycloaliphatic, aromatic and heterocyclic ring systems can be provided are, for example, halogen, nitro, cyano, di- (C_1-C_4) alkylamino, (C_1-C_4) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_4) trialkylsilyl, (C_1-C_4) alkoxy, (C_1-C_4) alkoxy- (C_1-C_4) alkyl, (C_1-C_4) alkoxy- $[\text{CH}_2\text{CH}_2\text{O}]_{0.1-2}$ -ethoxy, (C_1-C_4) alkylthio, (C_1-C_4) alkylsulfinyl, (C_1-C_4) alkylsulfonyl, phenyl, benzyl, phenoxy, halophenoxy, (C_1-C_4) alkylphenoxy, (C_1-C_4) alkoxyphenoxy, phenylthio, heterocyclyl, heterocyclylthio or heterocyclylloxy, it being possible for one or more, in the case of fluorine also up to the maximum number of, hydrogen atoms in the alkyl radicals and the radicals derived therefrom to be replaced by halogen, preferably chlorine or fluorine, where, in the event that these substituents are (C_1-C_4) alkyl, they may also be linked cyclically and where one or two aliphatic carbon units in these fused ring systems, such as, for example, the indane, di-, tetra- or decahydronaphthyl or benzocycloheptane sys-

tem, may be replaced by heteroatom units such as oxygen or sulfur and where one or more, in the case of fluorine also up to the maximum number of, hydrogen atoms on the aliphatic carbon atom units can be replaced by halogen or (C_1-C_4) alkyl.

It is also to be understood that enantiomeric and diastereomeric forms of the compounds of formulae (I) and salts thereof are embraced by the present invention.

By the term non-emetic is meant a compound that does not generally elicit emesis from the animal when a protective, preventative or cleaning dose is administered to the animal. By the term emesis is meant vomiting. Generally an emetic substance elicits the said emesis in less than 24 hours after administration, preferably less than 8 hours, more preferably less than 2 hours. Generally when the compounds of the invention are administered to a population of animals, more than 70% of the animals are free of emesis, preferably more than 80%, most preferably more than 90%.

Preferred compounds of the formula (I) are those wherein:

R_{201} is cyano, $\text{C}(\text{O})\text{alkyl}$, $\text{C}(\text{S})\text{NH}_2$, alkyl, $\text{C}(\text{=NOH})\text{NH}_2$ or $\text{C}(\text{=NNH}_2)\text{NH}_2$;

R_{202} is $\text{S}(\text{O})_k\text{R}_{203}$, C_1-C_4 alkoxy, C_1-C_4 haloalkoxy, cycloalkyl, halocycloalkyl, cycloalkyl-alkyl, C_2-C_3 alkoxy;

R_{203} is alkyl or haloalkyl;

R_{204} is $-\text{OH}$, $\text{R}_{205}\text{O}-$, $\text{HC}(\text{O})\text{O}-$, $\text{R}_{205}\text{C}(\text{O})\text{O}-$, $\text{R}_{205}\text{OC}(\text{O})\text{O}-$, $\text{NH}_2\text{C}(\text{O})\text{O}-$, $\text{R}_{205}\text{NHC}(\text{O})\text{O}-$, $\text{R}_{205}\text{R}_{206}\text{NC}(\text{O})\text{O}-$, $\text{R}_{205}\text{S}(\text{O})_k\text{C}(\text{O})\text{O}-$;

R_{205} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy-alkyl, haloalkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl,

R_{206} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy-alkyl, haloalkoxyalkyl, or R_{205} and R_{206} may form together with the nitrogen to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;

X_1 is selected from nitrogen and $\text{C}-\text{R}_{212}$;

R_{211} , R_{212} are independently selected from halogen, hydrogen, CN, and NO_2 ;

R_{213} is selected from halogen, haloalkyl, haloalkoxy, $-\text{S}(\text{O})_k\text{CF}_3$, and $-\text{SF}_3$;

R_{214} is hydrogen; and

b, k and n are independently selected from 0, 1, and 2.

Further compounds of formula (I) which are preferred according to the present invention are those wherein:

R_{201} is cyano;

R_{202} is $\text{S}(\text{O})_k\text{R}_{203}$;

R_{203} is alkyl or haloalkyl;

R_{204} is OH or R_{205}O ;

X_1 is selected from nitrogen and $\text{C}-\text{R}_{212}$;

R_{211} and R_{212} are independently selected from halogen, hydrogen, CN and NO_2 ;

R_{213} is selected from halogen, haloalkyl, haloalkoxy, $-\text{S}(\text{O})_k\text{CF}_3$, and $-\text{SF}_3$; and

b and k are independently selected from 0, 1, and 2.

The compounds of formula (I) of the present invention preferably have one or more of the following features:

R_{201} is cyano;

R_{202} is halomethyl, preferably CF_3 ;

R_{211} and R_{212} are independently halogen;

X_1 is $\text{C}-\text{R}_{212}$;


R_{213} is haloalkyl, haloalkoxy or $-\text{SF}_3$; or

b is 0 or 1, or 2.

5

A further embodiment of the invention includes compounds of the formula (I), with the proviso that if R_{201} is CN and R_{202} is $S(O)_m R_{203}$ then R_{204} is not $R_{203}O$ or $R_{203}R_{204}N-C(O)-O-$.

In another aspect of the present invention there is provided a method of controlling parasites in or on an animal by administering to the animal an 1-arylpyrazole of formula (II):



wherein:

R_{21} is cyano, $C(=S)NH_2$, $C(=NOH)NH_2$ or $C(=NNH_2)NH_2$;

R_{22} is $S(O)_m R_{23}$;

R_{23} is alkyl or haloalkyl;

R_{24} is OH, $HC(O)O-$, $R_{25}C(O)O-$, $R_{25}OC(O)O-$, $R_{25}R_{26}N-C(O)-O-$ or $R_{25}S(O)_m C(O)O-$;

R_{25} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted, C_2-C_6 alkenyl, C_2-C_6 alkynyl;

or two groups R_{25} may form together with the nitrogen to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;

X is selected from nitrogen and $C-R_{32}$;

R_{31} and R_{32} are independently selected from halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;

R_{33} is selected from halogen, haloalkyl, haloalkoxy, $-S(O)_m CF_3$, and $-SF_3$ or forms a ring together with R_{34} ;

R_{34} is hydrogen or may constitute together with R_{213} a group of OCF_2O , CF_2OCF_2 , CF_2OCF_2O and CF_2CF_2O , which forms together with the carbons they are attached to a five to six membered ring;

m is 0, 1 or 2;

r is selected from 0, 1, and 2;

and veterinarily acceptable salts thereof;

provided that if R_{21} is cyano then R_{24} is not $R_{25}R_{26}N-C(O)-O-$.

Preferred are compounds of formula (II),

wherein:

R_{21} is cyano, $C(=S)NH_2$, $C(=NOH)NH_2$ or $C(=NNH_2)NH_2$;

R_{22} is $S(O)_m R_{23}$;

R_{23} is alkyl or haloalkyl;

R_{24} is OH, $HC(O)O-$, $R_{25}C(O)O-$, $R_{25}OC(O)O-$ or $R_{25}S(O)_m C(O)O-$;

6

R_{25} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl;

X is selected from nitrogen and $C-R_{32}$;

R_{31} and R_{32} are independently selected from halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;

R_{33} is selected from halogen, haloalkyl, haloalkoxy, $-S(O)_m CF_3$, and $-SF_3$.

In another aspect of the present invention there is provided a compound of formula (II) or salt thereof as hereinbefore described with the proviso that the compound is not 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylthio-5-hydroxypyrazole.

A further preferred class of compounds of formula (II) are those wherein:

R_{21} is cyano;

R_{22} is $S(O)_m R_{23}$;

R_{23} is haloalkyl, preferably CF_3 ;

R_{24} is OH;

X is selected from nitrogen and $C-R_{32}$;

R_{31} and R_{32} are independently selected from halogen,

R_{33} is selected from halogen, haloalkyl, haloalkoxy, $-S(O)_m CF_3$, and $-SF_3$;


m and r are independently selected from 0, 1, and 2

with the proviso that the compound is not 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylthio-5-hydroxypyrazole.

In a further aspect of the invention the following groups of compounds are provided:

Compounds of the formula (I), wherein

R_{201} is $C(O)NH_2$, $C(O)NHR_{203}$, $C(O)NR_{203}R_{204}$, $C(O)N-S(R_{203})_2$, haloalkyl or heterocyclyl from the group:



optionally substituted by R_{203} ;

Compounds of the formula (I), wherein

R_{202} is nitro or imidazol-2-yl optionally substituted by alkyl, alkoxy, haloalkyl, halogen, cyano, nitro;

Compounds of the formula (I), wherein

R_{204} is $R_{205}SO_2O-$, aryl- SO_2O- , (C_1-C_7) -oxacycloalkyloxy, $R_{205}R_{206}N-C(NR_{203})-O-$, $R_{205}R_{206}N-C(NH)-O-$, $R_{205}NH-C(NR_{203})-O-$, $R_{205}NH-C(NH)-O-$, $R_{205}N=CH-O-$, $R_{205}N=C(R_{206})-O-$, $R_{205}NH-C(S)-O-$, $R_{205}R_{206}N-C(S)-O-$;

Compounds of the formula (I), wherein

R_{214} constitute together with R_{213} a group of OCF_2O , CF_2OCF_2 , CF_2OCF_2O and CF_2CF_2O , which forms together with the carbons they are attached to a five to six membered ring.

The compounds 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole and 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole are highly preferred compounds according to the invention.

The following compounds of formula (I) are preferred according to the present invention as listed in Tables 1 to 3. The Compound Numbers are for identification purposes only. The following symbols are hereby defined: Me means methyl; Et means ethyl; n-Pr means n-propyl; i-Pr means isopropyl; n-Bu means n-Butyl; and Ph means Phenyl.

208
205

TABLE 1

Compounds of formula (I) wherein R₂₀₁ is cyano;
R₂₀₂ is SCF₃; R₂₁₁ is Cl, X₁ is
C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃ or SF₅.
Phys. data: melting point (° C.) or NMR (¹H, ¹³F-NMR, ppm)

Compound Number (R ₂₁₁ = CF ₃)	Compound Number (R ₂₁₁ = SF ₅)	R ₂₀₄	Phys. data
1-1	1-2	OH	19F: -44.9 -63.8
2-1	2-2	OMe	mp. 83
3-1	3-2	OBi	mp. 105
4-1	4-2	OPr	
5-1	5-2	O-i-Pr	
6-1	6-2	O-n-Bu	
7-1	7-2	OCH ₂ OMe	
8-1	8-2	OCH ₂ CH ₂ OMe	
9-1	9-2	OCH ₂ OBi	
10-1	10-2	OCH ₂ CH ₂ OBi	
11-1	11-2	OC(O)Me	
12-1	12-2	OC(O)Bi	
13-1	13-2	OC(O)n-Pr	
14-1	14-2	OC(O)H	
15-1	15-2	OC(O)NH ₂	
16-1	16-2	OC(O)NHMe	
17-1	17-2	OC(O)NHEt	
18-1	18-2	OC(O)NHnPr	
19-1	19-2	OC(O)NMe ₂	mp. 126

TABLE 2

Compounds of formula (I) wherein R₂₀₁ is cyano;
R₂₀₂ is SOCF₃; R₂₁₁ is Cl, X₁
is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃ or SF₅.
Phys. data: melting point (° C.) or NMR (¹H, ¹³C-NMR, ppm)

Compound Number (R ₂₁₁ = CF ₃)	Compound Number (R ₂₁₁ = SF ₅)	R ₂₀₄	Phys. data
1-3	1-4	OH	mp. 185
2-3	2-4	OMe	mp. 136
3-3	3-4	OBi	mp. 157
4-3	4-4	OPr	
5-3	5-4	O-i-Pr	
6-3	6-4	O-n-Bu	
7-3	7-4	OCH ₂ OMe	
8-3	8-4	OCH ₂ CH ₂ OMe	
9-3	9-4	OCH ₂ OBi	
10-3	10-4	OCH ₂ CH ₂ OBi	
11-3	11-4	ONa	19F: -60.9 -72.6
12-3	12-4	OC(O)Bi	
13-3	13-4	OC(O)n-Pr	
14-3	14-4	OC(O)H	
15-3	15-4	OC(O)NH ₂	
16-3	16-4	OC(O)NHMe	
17-3	17-4	OC(O)NHEt	
18-3	18-4	OC(O)NHnPr	
19-3	19-4	OC(O)NMe ₂	

TABLE 3

Compounds of formula (I) wherein R₂₀₁ is cyano;
R₂₀₂ is SO₂CF₃; R₂₁₁ is Cl, X₁
is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃ or SF₅.
Phys. data: melting point (° C.) or NMR (¹H, ¹³F-NMR, ppm)

Compound Number (R ₂₁₁ = CF ₃)	Compound Number (R ₂₁₁ = SF ₅)	R ₂₀₄	Phys. data
1-5	1-6	OH	19F: -63.8 -79.9
2-5	2-6	OMe	mp. 151

TABLE 3-continued

Compounds of formula (I) wherein R₂₀₁ is cyano;
R₂₀₂ is SO₂CF₃; R₂₁₁ is Cl, X₁
is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃ or SF₅.
Phys. data: melting point (° C.) or NMR (¹H, ¹³F-NMR, ppm)

Compound Number (R ₂₁₁ = CF ₃)	Compound Number (R ₂₁₁ = SF ₅)	R ₂₀₄	Phys. data
3-5	3-6	OBi	mp. 132
4-5	4-6	OPr	
5-5	5-6	O-i-Pr	
6-5	6-6	O-n-Bu	
7-5	7-6	OCH ₂ OMe	
8-5	8-6	OCH ₂ CH ₂ OMe	
9-5	9-6	OCH ₂ OBi	
10-5	10-6	OCH ₂ CH ₂ OBi	
11-5	11-6	OC(O)Me	
12-5	12-6	OC(O)Bi	
13-5	13-6	OC(O)n-Pr	
14-5	14-6	OC(O)H	
15-5	15-6	OC(O)NH ₂	
16-5	16-6	OC(O)NHMe	
17-5	17-6	OC(O)NHEt	
18-5	18-6	OC(O)NHnPr	
19-5	19-6	OC(O)NMe ₂	

TABLE 4

Compounds of formula (I) wherein R₂₀₁ is alkyl or
haloalkyl; R₂₀₂ is SO₂R₂₀₃;
R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃.
Phys. data: melting point (° C.) or NMR (¹H, ¹³F-NMR, ppm)

Compound No	R ₂₀₁	R ₂₀₂	R ₂₀₄	Phys. Data
1-7	CH ₃	SCF ₃	OH	19F: -45.9 -63.5
2-7	CH ₃	SOCF ₃	OH	
3-7	CH ₃	SO ₂ CF ₃	OH	
4-7	CH ₃	SOCCl ₃	OH	19F: -30.4 -63.7
5-7	CH ₃	SOCCF ₃	OH	
6-7	CH ₃	SO ₂ CCF ₃	OH	
7-7	CH ₃	SOCCl ₂ F	OH	
8-7	CH ₃	SOCCl ₂ F	OH	
9-7	CH ₃	SC ₂ F ₅	OH	
10-7	CH ₃	SC ₂ F ₅	OH	
11-7	CH ₃	SCF ₃	OMe	
12-7	CH ₃	SCF ₃	OBi	
13-7	CH ₃	SiMe ₃	OH	
14-7	C ₂ H ₅	SCF ₃	OH	
15-7	CF ₃	SCF ₃	OH	
16-7	CHF ₂	SCF ₃	OH	
17-7	CF ₃	SOCCF ₃	OH	
18-7	CF ₃	SO ₂ CF ₃	OH	
19-7	CF ₃	SOCCl ₂ F	OH	
20-7	CF ₃	SOCCl ₂ F	OH	

TABLE 5

Compounds of formula (I) wherein R₂₀₁ is SO₂R₂₀₂;
R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄
is H and R₂₁₃ is CF₃.
Phys. data: melting point (° C.) or NMR (¹H, ¹³F-NMR, ppm)

Compound No	R ₂₀₁	R ₂₀₂	R ₂₀₄	Phys. data
1-8	CONH ₂	SCF ₃	OH	mp. 197
2-8	CONH ₂	SOCCF ₃	OH	

TABLE 5-continued

Compounds of formula (I) wherein R_{201} is SO_2R_{202} ; R_{211} is Cl, X_1 is C—Cl, R_{214} is H and R_{213} is CF_3 ; Phys. data: melting point (° C.) or NMR (1H , ^{19}F -NMR, ppm)				
Compound No	R_{202}	R_{204}	Phys. data	
3-8	$CONH_2$	SO_2CF_3	OH	
4-8	$CSNH_2$	SCF_3	OH	
5-8	$CSNH_2$	SO_2CF_3	OH	
6-8	$CSNH_2$	SO_2CF_3	OH	
7-8	$CONMe_2$	SCF_3	OH	
8-8	$C(NOH)NH_2$	SO_2CF_3	OH	mp. 156
9-8	$C(NOH)NH_2$	SCF_3	OH	mp. 184
10-8	$COCH_3$	SCF_3	OH	19F: -44.5 -61.7
11-8	$COCH_3$	SO_2CF_3	OH	19F: -29.4 -61.0
12-8	$CONH_2$	SCF_3	OH	
13-8	$CONH_2$	SO_2CF_3	OH	
14-8	Oxidiazolin-3-yl	SCF_3	OH	
15-8	Oxidiazolin-2-yl	SCF_3	OH	
16-8	$CON-S(Pr)_2$	SCF_3	OH	
17-8	$CON-S(Pr)_2$	SO_2CF_3	OH	
18-8	$CON-S(Pr)_2$	SO_2CF_3	OH	
19-8	$CONH_2$	SCF_3	OMe	mp. 148-151

TABLE 6

Compounds of formula (I) wherein R_{201} is CN; R_{202} is SO_2R_{203} ; R_{211} is Cl, X_1 is C—Cl, R_{214} is H and R_{213} is CF_3 ; Phys. data: melting point (° C.) or NMR (1H , ^{19}F -NMR, ppm)			
Compound No	R_{203}	R_{204}	Phys. data
1-9	SO_2CF_3	OH	19F: -30.7 -63.7
2-9	SO_2CF_3	OH	
3-9	SO_2CF_3	OH	
4-9	SO_2CF_3	OH	
5-9	SO_2CF_3	OH	
6-9	SO_2CF_3	OH	
7-9	SCF_3	OH	
8-9	SO_2CF_3	OH	
9-9	SO_2CF_3	OH	
10-9	SO_2CF_3	OH	
11-9	SCF_3	OH	1H: 1.25, 3H: 3.71, 3H: 7.72, 2H:
12-9	SO_2CF_3	OH	
13-9	SO_2CF_3	OH	mp. 91
14-9	SO_2CF_3	OH	mp. 161
15-9	SO_2CF_3	OH	
16-9	SO_2CF_3	OH	
17-9	SO_2CF_3	OH	mp. 66
18-9	SO_2CF_3	OH	1H: 2.43, 3H: 2.96, 6H: 7.75, 2H:
19-9	SO_2CF_3	OH	
20-9	SO_2CF_3	OH	
21-9	SO_2CF_3	OH	mp. 154
22-9	SO_2CF_3	OH	mp. 136

TABLE 6-continued

Compounds of formula (I) wherein R_{201} is CN; R_{202} is SO_2R_{203} ; R_{211} is Cl, X_1 is C—Cl, R_{214} is H and R_{213} is CF_3 ; Phys. data: melting point (° C.) or NMR (1H , ^{19}F -NMR, ppm)			
Compound No	R_{203}	R_{204}	Phys. data
23-9	SO_2CF_3	OMe	mp. 188
24-9	SO_2CF_3	OMe	mp. 130
25-9	SO_2CF_3	OMe	mp. 87
26-9	SO_2CF_3	OMe	mp. 139
27-9	SO_2CF_3	OMe	mp. 166

TABLE 7

Compounds of formula (I) wherein R_{201} is CN; R_{202} is SO_2R_{203} ; R_{211} is Cl, X_1 is C—Cl, R_{214} is H and R_{213} is CF_3 ; Phys. data: melting point (° C.) or NMR (1H , ^{19}F -NMR, ppm)			
Compound No	R_{203}	R_{204}	Phys. data
1-10	SCF_3	OCH_2-CCH	19F: -44.6 -63.8
2-10	SCF_3	OCH_2COOEt	mp. 71
3-10	SCF_3	$OCOCu$	mp. 62
4-10	SCF_3	$OCO-Ph-4-OMe$	19F: -43.5 -63.9
5-10	SCF_3	OSO_2Me	mp. 110
6-10	SCF_3	$OCO-Pyrrolidine$	mp. 201
7-10	SCF_3	$OCO-Morpholine$	19F: -43.5 -63.8
8-10	SCF_3	$OCO-N(i-Pr)_2$	mp. 120
9-10	SCF_3	$OCO-NPh_2$	mp. 142
10-10	SCF_3	$OCO-N(Me)Ph$	19F: -43.6 -63.7
11-10	SCF_3	$OCO-Carbazole$	mp. 148
12-10	SCF_3	$OCO-Adamsyl$	mp. 142
13-10	SCF_3	$OCO-Mesityl$	mp. 103
14-10	SCF_3	$OCCH_2Ph$	mp. 73
15-10	SCF_3	$OSO_2-4-Tolyl$	
16-10	SCF_3	$O-C(NMe)_2NMe_2$	
17-10	SCF_3	$O-CH-NC_2H_4OEt$	
18-10	SCF_3	OCH_2CONH_2	mp. 156
19-10	SCF_3	$O-C(N(i-Pr))NHPr$	
20-10	SCF_3	$O-C(i-Pr)-NHPr$	

TABLE 8

Compounds of formula (I) wherein R_{201} is Cl, X_1 is C—Cl, R_{214} is H and R_{213} is CF_3 ; Phys. data: melting point (° C.) or NMR (1H , ^{19}F -NMR, ppm)				
Compound No	R_{202}	R_{203}	R_{204}	Phys. data
1-11	CN	4,5-Dicyanotrimethyl-2-yl	OH	
2-11	CN	4,5-Dicyanotrimethyl-2-yl	OH	
3-11	CH_3	4,5-Dicyanotrimethyl-2-yl	OH	

210
207

TABLE 8-continued

Compounds of formula (I) wherein R ₂₁₁ is Cl, X ₁ is C—Cl, R ₂₁₄ is H and R ₂₁₅ is CF ₃ ; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm)				
Compound No	R ₂₀₁	R ₂₀₂	R ₂₀₄	Phys. data
4-11	CH ₃	4,5-Dicyanimidazol-2-yl	OBz	1H: 1.24, 3H; 2.55, 3H; 4.08, 2H; 7.77, 2H;
5-11	CN	—CH=CCl ₂	OBz	
6-11	CN	—CH ₂ CH=CH ₂	OAllyl	mp. 82-86
7-11	CN	—CH=CHCl ₂	OBz	
8-11	CN	Cyclopropyl	OBz	
9-11	CN	n-C ₆ H ₁₁	OBz	
10-11	CN	NO ₂	OEt	mp. 107
11-11	CN	NO ₂	OBz	
12-11	CN	—CC—Me	OBz	
13-11	CN	—CC—SiMe ₃	OBz	

25

METHODS OF SYNTHESIS

TABLE 9

Compounds of formula (I) wherein R ₂₀₁ is CN; R ₂₀₂ is SO ₂ R ₂₀₃ ; R ₂₁₁ is Cl, R ₂₁₄ and R ₂₁₅ form the unit CF ₂ OCF ₂ ; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm)				
Compound No	R ₂₀₃	R ₂₀₄	X = CR ₂₁₂	Phys. data
1-12	SCF ₃	OH	CH	
2-12	SCF ₃	OH	C—Cl	
3-12	SCF ₃	OBz	C—Cl	
4-12	SOCF ₂	OH	CH	
5-12	SOCF ₂	OH	C—Cl	
6-12	SO ₂ CF ₃	OH	CH	
7-12	SO ₂ CF ₃	OH	C—Cl	
8-12	SOClF ₂	OH	C—Cl	
9-12	SOCl ₂ F	OH	C—Cl	
10-12	SC ₂ H ₅	OH	C—Cl	



TABLE 10

Compounds of formula (I) wherein R ₂₀₁ is CN; R ₂₀₂ is SO ₂ R ₂₀₃ ; R ₂₁₁ is Cl, X ₁ is C—Cl, R ₂₁₄ is H and R ₂₁₅ is OCF ₃ ; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm)			
Compound No	R ₂₀₃	R ₂₀₄	Phys. data
1-13	SCF ₃	OH	
2-13	SOCF ₂	OH	
3-13	SO ₂ CF ₃	OH	
4-13	SCF ₃	OMe	mp. 101
5-13	SOCF ₂	OMe	mp. 104
6-13	SO ₂ CF ₃	OMe	mp. 117
7-13	SOCl ₂ F	OMe	mp. 123
8-13	SCF ₃	OBz	
9-13	SOCF ₂	OBz	
10-13	SO ₂ CF ₃	OBz	

Method 1


The compounds of formula (I) and (II) with R₂₀₄/R₂₄=OH and R₂₂=SR₂₃ can be synthesized by reacting 5-hydroxy-pyrazoles with sulfonylchlorides with or without bases in organic solvents (see e.g. EP-A-295 117):

METHOD 2




The compounds of formula (I) and (II) with R₂₀₄/R₂₄=OH and R₂₂=SR₂₃ can be synthesized by reacting 5-hydroxy-

pyrazoles with disulfur dichloride. The resulting pyrazole-disulfides can be alkylated to yield 4-pyrazolsulfides (see e.g., EP-A-374 061, EP295117, C. Wakselman, *J. Chem. Soc. Perkin Trans 1*, 1992, 3371-3375):



The compounds of formula (I) and (II) with $R_{204}/R_{214}=\text{OH}$ and $R_{22}=\text{S(O)}_nR_{23}$ ($n=1,2$) can be synthesized by reacting pyrazolsulfides $R_{22}=\text{SR}_{23}$ with oxidizing agents like peroxy compounds (hydrogen peroxide, organic peroxides as peroxyacetic acid), halogen derivatives (like periodate salts) and others to obtain sulfoxides $R_{22}=\text{SOR}_{23}$ and sulfones $R_{22}=\text{SO}_2R_{23}$ (see e.g. EP-A-295 117).



In another aspect of the present invention, compounds of formula (II) wherein R_{24} is $\text{HC(O)O}-$, $\text{R}_{25}\text{C(O)O}-$, $\text{R}_{25}\text{OC(O)O}-$, or $\text{R}_{25}\text{S(O)}_n\text{C(O)O}$ and R_{21} , R_{22} , R_{31} , R_{33} , X and n are defined above are generally prepared by reaction of compounds of formula (II) wherein R_{24} is OH and R_{21} , R_{22} , R_{31} , R_{33} , X and n are defined above with compounds of formulae (III), (IV), (V), and (VI) respectively wherein X_2 is a leaving group such as a halogen atom or an acetyl group:



Compounds of general formula (II) wherein R_{24} is OH and R_{21} , R_{22} , R_{31} , R_{33} , X and n are defined above may be prepared by methods known in the art generally or by methods described in International Patent Publications WO 94/21606, WO 97/07102, WO 98/24767, WO 98/28277, WO 98/28278 and WO 98/28279, European Patent Application 385809, and U.S. Pat. No. 5,232,940, 5,047,350 or other methods known to the person skilled in the art.

The present invention also relates to a composition comprising a parasitocidally effective, substantially non-emetic amount of a compound of formula (I) or a salt thereof and an acceptable carrier. Acceptable carriers for the use of the compounds are generally known to the skilled addressee concerned with pest control in animals, particularly domestic animals, most preferably dogs or cats.

The compositions which can be used in the invention can comprise generally from about 0.001 to 95% of the compound of formula (I) or a salt thereof. The remainder of the composition up to 100% comprises a carrier as well as generally various additives. In this specification and the accompanying claims, percentages are by weight.

The diluted liquid formulations generally comprise from about 0.001 to about 3% of compound of formula (I) or a salt thereof, preferably from about 0.1 to about 0.5%.

Solid formulations generally comprise from about 0.1 to about 8% of compound of formula (I) or a salt thereof, preferably from about 0.5 to about 1.5%.

Compositions for oral administration comprise one or more of the compounds of general formula (I) or salts thereof in association with veterinarily acceptable carriers or coatings and include, for example, tablets, pills, capsules, gels, drenches, medicated feeds, medicated drinking water.

medicated dietary supplements, slow-release boluses or other slow-release devices intended to be retained within the gastro-intestinal tract. Any of these may incorporate the active ingredients contained within micro-capsules or coated with acid-labile or alkali-labile or other pharmaceutically acceptable enteric coatings. Feed premixes or concentrates containing compounds of the present invention for use in preparation of medicated diets, drinking water or other materials for consumption by animals may also be used. In a highly preferred embodiment, the compositions are administered postprandially, preferably from just after a meal to 2 hours after the meal.

In a highly preferred embodiment, there is provided a product which is readily chewed by the animal and which product does generally not allow human contamination when the product is provided to the animal by hand.

The compounds of general formula (I) or salts thereof may be administered before, during or after meals. The compounds of general formula (I) or salts thereof may be mixed with a carrier and/or a feedstuff.

According to the present invention the compound of formula (I) or a salt thereof is administered orally in a dose to the animal in a dose range generally from 0.1 to 500 mg/kg of the compound of formula (I) or a salt thereof per kilogram of animal body weight (mg/kg), preferably from 1 to 100 mg/kg, more preferably from 1 to 50 mg/kg, even more preferably from 2 to 25 mg/kg, most preferably from 3 to 15 mg/kg.

According to the present invention, the frequency of treatment of the animal, preferably the domestic animal to be treated by the compound of formula (I) or a salt thereof is generally from about once per week to about once per year, preferably from about once every two weeks to about once every six months, more preferably from about once every two weeks to once every three months, and most preferably from about once every two weeks to about once every six weeks.

Generally the animal to be treated is a domestic animal, preferably a domestic companion animal. More preferably the animal to be treated is a dog and/or a cat.

Accordingly, in a preferred embodiment there is provided a method of controlling parasites in or on a cat comprising administering orally to the cat a parasitically effective, substantially non emetic amount of a 1-arylpyrazole of formula (I).

In a further preferred embodiment there is provided a method of controlling parasites in or on a dog comprising administering orally to the dog a parasitically effective, substantially non emetic amount of a 1-arylpyrazole of formula (I).

The present invention also relates to a composition comprising a parasitically effective amount of a compound of formula (II) or a salt thereof and an acceptable carrier. Acceptable carriers for the use of the compounds are generally known to the skilled addressee concerned with pest control in animals, particularly domestic animals, most preferably dogs or cats.

In another aspect of the present invention, the compounds of formula (II) or salts thereof may be used in the field of veterinary medicine or livestock husbandry or in the maintenance of public health against arthropods, helminths or protozoa which are parasitic internally or externally upon vertebrates, particularly warm-blooded vertebrates, for example domestic animals, e.g., cattle, sheep, goats, equines, swine, poultry, dogs or cats.

The compounds are administered to animals infested by or exposed to infestation by arthropods, helminths or pro-

tozoa, by parenteral, oral or topical application of compositions in which the active ingredient exhibits an immediate and/or prolonged action over a period of time against the arthropods, helminths or protozoa, for example by incorporation in feed or suitable orally-ingestible pharmaceutical formulations, edible baits, salt licks, dietary supplements, pour-on formulations, sprays, baths, dips, showers, jets, dusts, greases, shampoos, creams, wax smeers or livestock self-treatment systems.

Solid or liquid compositions for application topically to animals, timber, stored products or household goods usually contain from about 0.00005% to about 90%, more particularly from about 0.001% to about 10%, by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof. For administration to animals orally or parenterally, including percutaneously, in solid or liquid compositions, these normally contain from about 0.1% to about 90% by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof. Medicated feedstuffs normally contain from about 0.001% to about 3% by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof. Concentrates or supplements for mixing with feedstuffs normally contain from about 5% to about 90%, preferably from about 5% to about 50%, by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof. Mineral salt licks normally contain from about 0.1% to about 10% by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof.

Dusts or liquid compositions for application to livestock, goods, premises or outdoor areas may contain from about 0.0001% to about 15%, more especially from about 0.005% to about 2.0%, by weight, of one or more compounds of formula (II) or veterinarily acceptable salts thereof. Suitable concentrations in treated waters are between about 0.0001 ppm and about 20 ppm, more particularly about 0.001 ppm to about 5.0 ppm, of one or more compounds of formula (II), or veterinarily acceptable salts thereof, and may be used therapeutically in fish farming with appropriate exposure times. Edible baits may contain from about 0.01% to about 5%, preferably from about 0.01% to about 1.0%, by weight, of one or more compounds of formula (II) or veterinarily acceptable salts thereof.

When administered to vertebrates parenterally, orally or by percutaneous or other means, the dosage of compounds of formula (II), or veterinarily acceptable salts thereof, will depend upon the species, age, or health of the vertebrate and upon the nature and degree of its actual or potential infestation by arthropod, helminth or protozoan pests. A single dose of about 0.1 to about 500, preferably from 0.1 to about 100 mg, preferably about 2.0 to about 20.0 mg, per kg body weight of the animal or doses of about 0.01 to about 20.0 mg, preferably about 0.1 to about 5.0 mg, per kg body weight of the animal per day, for sustained medication, are generally suitable by oral or parenteral administration. By use of sustained release formulations or devices, the daily doses required over a period of months may be combined and administered to animals on a single occasion.

The compounds of the invention may be administered most advantageously with another parasitically effective material, such as an endoparasiticide, and/or an ectoparasiticide, and/or an endectoparasiticide. For example, such compounds include macrocyclic lactones such as avermectins or milbemycins e.g., ivermectin; pyralol (generally administered as pyralol pamoate) or an insect growth regulator such as lufenuron or methoprene.

By the term "parasites" as used in the specification and claims is meant endoparasites and ectoparasites of warm-blooded animals, particularly ectoparasites. Preferably, fleas and/or ticks are controlled by the method of the present invention.

Illustrative of specific parasites of various host animals which may be controlled by the methods of this invention include arthropods such as:

Mites: *Mesostigmata* spp. e.g., mesostigmatids such as the chicken mite, *Dermanyssus gallinae*; itch or scab mites such as *Sarcoptes* spp. for example *Sarcoptes scabiei*; mange mites such as *Psoroptes* spp. including *Chorioptes bovis* and *Psaroptes ovis*; chiggers e.g., *Trombiculidae* spp. for example the north american chigger, *Trombicula alfreddugesi*;

Ticks: e.g., soft-bodied ticks including *Argasidae* spp. for example *Argas* spp. and *Ornithodoros* spp.; hard-bodied ticks including *Ixodidae* spp., for example *Rhipicephalus sanguineus*, and *Boophilus* spp.;

Lice: sucking lice, e.g., *Menopon* spp. and *Bovicola* spp.; biting lice, e.g., *Haematopinus* spp., *Linognathus* spp. and *Solenopotes* spp.;

Fleas: e.g., *Ctenocephalides* spp., such as dog flea (*Ctenocephalides canis*) and cat flea (*Ctenocephalides felis*); *Xenopsylla* spp. such as oriental rat flea [*Xenopsylla cheopis*]; and *Pulex* spp. such as human flea [*Pulex irritans*];

True bugs: e.g., *Cimicidae* or including the common bed bug (*Cimex lectularius*); *Triatominae* spp. including triatomid bugs also known as kissing bugs; for example *Rhodnius prolixus* and *Triatoma* spp.;

bloodsucking adult flies: (e.g., horn fly [*Haematobia irritans*], horse fly [*Tabanus* spp.], stable fly [*Stomoxys calcitrans*], black fly [*Simulium* spp.], deer fly [*Chrysops* spp.], louse fly [*Melophagus ovinus*], tsetse fly [*Glossina* spp.], mosquitoes [*Culex* spp., *Anopheles* spp., and *Aedes* spp.); and

parasitic fly maggots: (e.g., bot fly [*Oestrus ovis* and *Cuterebra* spp.], blow fly [*Phaenicia* spp.], screwworm [*Cochliomyia hominivorax*], cattle grub [*Hypoderma* spp.], fleece worm.

The present invention also provides for the use of a compound of formula (I) or a salt thereof hereinbefore described as a therapeutic agent, preferably for animals, more preferably for domestic animals.

The veterinary composition may be sterile or non-sterile. It may be a liquid (e.g., aqueous) or solid (e.g., dry) composition, in particular a freeze-dried composition, from which, by addition of water or another liquid, orally effective solutions may be prepared.

The present invention also provides for the use of a compound of formula (I) or a salt thereof as hereinbefore defined for the manufacture of a veterinary composition for the control of parasites in or on an animal.

In a further embodiment of the invention there is provided the use of a compound of formula (I) or salt thereof for controlling parasites in or on an animal without causing emesis of the animal.

Preferred is the use for orally administering the compound to the animal, which is preferably a domestic animal, highly preferred a cat or a dog.

In a further embodiment of the invention there is provided the use of a compound of formula (I) or salt thereof for the manufacture of a substantially non-emetic composition, for controlling parasites in or on an animal, preferably for oral administering.

The present invention also relates to a method of cleaning animals in good health comprising the application to the

animal of a compound of formula (I) or a salt thereof as hereinbefore defined to the animal.

The method of cleaning an animal is not a method of treatment by therapy of the animal body per se, because

(a) the animal is in good health and requires no substantial treatment to correct a deficiency of health;

(b) the cleaning of the animal is not intended to be done by veterinary personnel, but by persons interested in the cleaning of the animal; and

(c) the purpose of such cleaning is to avoid unpleasant conditions for humans and the environment in which humans inhabit so as to not infect the said humans with arthropods carried by the animal.

By "carrier" is meant an organic or inorganic material, which can be natural or synthetic, and which is associated with the compound and which facilitates its application to the animal. This carrier is thus generally inert and should be arthropodically acceptable. The carrier can be solid (e.g., clay, silicates, silica, resins, wax) or liquid (e.g., water, alcohols, ketones, oil solvents, polar aprotic solvents). An example of an oil solvent is corn oil. An example of a polar aprotic solvent is dimethyl sulfoxide.

The compounds of the invention also have utility in the control of arthropod or nematode pests of plants. The active compound is generally applied to the locus in which arthropod or nematode infestation is to be controlled at a rate of about 0.005 kg to about 25 kg of active compound per hectare of locus treated, preferably 0.02 to 2 kg/ha. Under ideal conditions, depending on the pest to be controlled, the lower rate may offer adequate protection. On the other hand, adverse weather conditions, resistance of the pest and other factors may require that the active ingredient be used in higher proportions. For foliar application, a rate of 0.01 to 1 kg/ha may be used.

When the pest is soil-borne, the formulation containing the active compound is distributed evenly over the area to be treated in any convenient manner. Application may be made, if desired, to the field or crop-growing area generally or in close proximity to the seed or plant to be protected from attack. The active component can be washed into the soil by spraying with water over the area or can be left to the natural action of rainfall. During or after application, the formulation can, if desired, be distributed mechanically in the soil, for example by ploughing or disking. Application can be prior to planting, at planting, after planting but before sprouting has taken place or after sprouting.

The compounds of the invention may be applied in solid or liquid compositions to the soil principally to control those nematodes dwelling therein but also to the foliage principally to control those nematodes attacking the aerial parts of the plants (e.g., *aphelenchoides* spp. and *ditylenchus* spp. listed above).

The compounds of the invention are of value in controlling pests which feed on parts of the plant remote from the point of application, e.g., leaf feeding insects are killed by the subject compounds applied to roots. In addition the compounds may reduce attacks on the plant by means of antifeeding or repellent effects.

The compounds of the invention are of particular value in the protection of field, forage, plantation, glasshouse, orchard and vineyard crops, or ornamentals and of plantation and forest trees, for example, cereals (such as maize, wheat, rice, sorghum), cotton, tobacco, vegetables and salads (such as beans, cole crops, cucurbits, lettuce, onions, tomatoes and peppers), field crops (such as potato, sugar beet, ground nuts, soyabean, oil seed rape), sugar cane, grassland and forage (such as maize, sorghum, lucerne),

57
243
210

19

plantations (such as of tea, coffee, cocoa, banana, oil palm, coconut, rubber, spices), orchards and groves (such as of stone and pip fruit, citrus, kiwifruit, avocado, mango, olives, and walnuts), vineyards, ornamental plants, flowers and shrubs under glass and in gardens and parks, forest trees (both deciduous and evergreen) in forests, plantations and nurseries.

They are also valuable in the protection of timber (standing, felled, converted, stored or structural) from attack by sawflies (e.g., urocerus) or beetles (e.g., scolytids, platypodids, lycids, bostrychids, cerambycids, anobiids), or termites, for example, *reticulitermes* spp., *heterotermes* spp., *copiotermes*.

They have applications in the protection of stored products such as grains, fruits, nuts, spices and tobacco, whether whole, milled or compounded into products, from moth, beetle and mite attack. Also protected are stored animal products such as skins, hair, wool and feathers in natural or converted form (e.g., as carpets or textiles) from moth and beetle attack; also stored meat and fish from beetle, mite and fly attack.

The disclosure in U.S. provisional application No. 60/168,658 from which this application claims priority is incorporated herein by reference.

The invention is further illustrated by the following examples, without limiting it thereto.

EXAMPLES AND PREPARATIONS

Example 1

Preparation of 1-(2,6-Dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole

To a solution of 15 g (35.5 mmol) of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole in 125 ml of dichloromethane at room temperature was added a solution of *m*-chloroperbenzoic acid (8.76 g, 70%, 35.5 mmol) in 375 ml of dichloromethane. The resulting solution was stirred at room temperature for 17 hr. It was then concentrated and triturated with ethyl acetate and heptane(1:2). Upon filtration a solid was obtained. This solid was dissolved in ethyl acetate and stirred with saturated sodium bicarbonate solution. The layers were separated and the aqueous layer was extracted three times with ethyl acetate. The combined organic layer was dried (magnesium sulfate) and concentrated. Upon chromatographic purification via silica gel column, a solid (5.7 g, 13.01 mol, 37%) was obtained as the desired product, mp 185–187d.

Example 2

Preparation of 1-(2,6-Dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole

To the solution of 2 g (4.74 mmol) of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole in 1,2-dichloroethane was added 1.83 ml (9.52 mmol, 35% in acetic acid) of peracetic acid at room temperature. The resulting solution was heated up to 60 C for 9 hr. It was then cooled and concentrated to give 2.05 g of residue. Upon chromatographic purification via silica gel column eluting with gradient solvent mixture (heptane/ethyl acetate), an oil (1.08 g, 2.38 mmol, 50.2% yield) was obtained as the desired product with 98% HPLC purity; F-NMR, -60.999 ppm (AR—CF₃), -79.893 ppm (SO₂CF₃). H-NMR, 8.18 ppm (s, 2H).

20

Example 3

Preparation of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-amido-4-trifluoromethylsulfonyl-5-hydroxypyrazole

To the mixture of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole (3.0 g, 7.13 mmol) and concentrated sulfuric acid (3 ml) was heated at 100 C for 3 hr. The reaction mixture was cooled and poured into ice-water. A solid was collected via filtration and was washed with water. It was then vacuum dried to obtain a solid (2.88 g, 6.56 mmol, 92% yield) with 98% HPLC purity, m. p. 197–198 C.

Example 4

Preparation of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-thioamido-4-trifluoromethylsulfonyl-5-hydroxypyrazole

The mixture of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-amido-4-trifluoromethylsulfonyl-5-hydroxypyrazole (1 g, 2.28 mmol) and Lawesson's reagent (0.49 g, 1.21 mmol) in toluene was heated up to reflux for 4 hr. The reaction mixture turned into a solution during this time. This solution was then cooled, concentrated, and purified via chromatographic purification to provide a solid (0.283 g, 0.623 mmol, 27.3% yield) with 96% HPLC purity m. p. 150–151 decomp.

Example 5

Preparation of 1-(2,6-Dichloro-4-trifluoromethylphenyl)-3-oximicamido-4-trifluoromethylsulfonyl-5-hydroxypyrazole

To the solution of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole (3.0 g, 7.11 mmol) in 15 ml of methanol at room temperature was added hydroxylamine hydrochloride (0.59 g, 8.53 mmol) and triethylamine (0.94 g, 9.24 mmol). The resulting mixture was stirred at room temperature for a total of 48 hr with additional hydroxylamine hydrochloride (1.18 g, 17.06 mmol) and triethylamine (1.88 g, 18.5 mmol) added portionwise. The resulting reaction mixture was concentrated and then dissolved in ethyl acetate. The organic layer was washed with saturated ammonium chloride, water, dried (sodium sulfate), and concentrated to give a brown oil which solidified after standing, m. p. 184 C.

Example 6

Preparation of 1-(2,6-Dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-trimethylacetoxypyrazole

To the solution of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole (7.00 g, 16.6 mmol) and pyridine (4.91 g, 62.1 mmol) in 1,2-dichloroethane at room temperature was added trimethylacetyl chloride (4.37 g, 36.2 mmol) dropwise. Ice bath was used to maintain the temperature of the reaction. After 20 hr at room temperature, the organic layer was washed five times with aqueous KHSO₄ till the aqueous solution was at pH 1. The organic layer was then dried (MgSO₄) and concentrated to give a solid residue. Upon chromatographic purification via silica gel column of the solid residue, after trituration with pentane, a off-white solid (2.403 g, 28.6% yield, 97.0% HPLC purity) was provided as the desired product, m. p. 82–83 C.

214
211

21

Example 7

Preparation of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-chlorodifluoromethylsulfonyl-5-hydroxypyrazole

To the solution of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-5-hydroxypyrazole (12.0 g, 37.3 mmol.) and pyridine (3.25 g, 41.0 mmol) in dichloromethane at -50 to -60 C was added chlorodifluoromethanesulfonyl chloride (8.1 g, 46.6 mmol). The resulting solution was gradually warmed up to room temperature. After 20 hr, the organic layer was washed five times with water. It was then washed with brine and dried (Na_2SO_4) to provide an oil. Upon chromatographic purification of the oil, a total of 11.6 g (26.4 mmol., 71% yield) of the desired product with 97% HPLC purity was isolated. F-NMR: -30.05 ppm (CClF_2), -63.80 ppm (ArCF_3).

BIOLOGICAL EXAMPLE

The compounds 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylthio-5-hydroxypyrazole, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole and 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole are formulated as 30 mg/mL formulations in a 1:1 volume/volume solution of dimethyl sulfoxide and corn oil. Using this formulation, mixed breed dogs and cats are treated at a rate of 10 mg of the compound per kg (mg/kg) of body weight of the dog and 20 mg/kg of the cat treated. The animals are fasted for at least 8 hours prior to treatment, fed half of the daily ration immediately prior to treatment, then allowed access to the remainder of the daily ration immediately following treatment.


All dogs are infested with cat fleas (*Ctenocephalides felis*) and with ticks (*Rhipicephalus sanguineus*) 1 day prior to administration of the compound. Cats are only infested with fleas. The initial flea and tick counts are performed 1 day after the administration of the compounds. At 7, 14, 21 and 28 days after treatment the dogs are re-infested with ticks and 8, 15, 22 and 29 days after treatment the dogs and cats are re-infested with fleas. At 1, 9, 16, 23 and 30 days after treatment the control of fleas and ticks in treated dogs and cats is determined versus a group of infested dogs and cats which receive a placebo consisting of a 1:1 volume/volume solution of dimethyl sulfoxide and corn oil. To determine the efficacies of the compounds, the arthropods are combed from the animals and counted.

Satisfactory results are obtained for many of the above-mentioned compounds in any of the three areas of evaluation without any significant side-effect for a period ranging from eight to thirty days: control of flea on dog, control of tick on dog, and control of flea on cat. They are: 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-trimethylacetoxypyrazole 3-10, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-ethoxypyrazole 3-1, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-chlorodifluoromethylsulfonyl-5-hydroxypyrazole 1-9, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole 1-1, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole 1-5, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole 1-3, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-N,N-dimethylcarbamoyloxypyrazole 19-1.

22

What is claimed is:

1. A compound having the formula (II):



wherein:

R_{21} is cyano, $\text{C}(=\text{S})\text{NH}_2$, $\text{C}(=\text{NOH})\text{NH}_2$ or $\text{C}(=\text{NNH}_2)\text{NH}_2$;

R_{22} is $\text{S}(O)_m R_{23}$;

R_{23} is alkyl or haloalkyl;

R_{24} is OH , $\text{HC}(\text{O})\text{O}-$, $\text{R}_{25}\text{C}(\text{O})\text{O}-$, $\text{R}_{25}\text{OC}(\text{O})\text{O}-$, $\text{R}_{25}\text{R}_{26}\text{N}-\text{C}(\text{O})\text{O}-$ or $\text{R}_{25}\text{S}(O)_n\text{C}(\text{O})\text{O}-$;

R_{25} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, heteraryl optionally substituted, arylalkyl optionally substituted, heterarylalkyl optionally substituted, C_2-C_6 alkenyl or C_2-C_6 alkynyl;

or two groups R_{25} form together with the nitrogen to which they are attached a 3 to 7 membered ring which optionally has one or more additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;

X is $\text{C}-R_{33}$;

R_{31} and R_{32} are independently selected from the group consisting of halogen, hydrogen, CN , C_1-C_3 alkyl and NO_2 ;

R_{33} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-\text{S}(O)_n\text{CF}_3$ and SF_6 ;

r is selected from the group consisting of 0, 1 and 2; and when R_{21} is cyano, m is selected from the group consisting of 1 and 2, or

when R_{21} is other than cyano, m is selected from the group consisting of 0, 1 and 2;

or a veterinarily acceptable salt thereof;

provided that when R_{21} is cyano, then R_{24} is not $\text{R}_{25}\text{R}_{26}\text{N}-\text{C}(\text{O})\text{O}-$.

2. A compound according to claim 1, wherein:

R_{21} is cyano;

R_{22} is $\text{S}(O)_m R_{23}$;

R_{23} is haloalkyl;

R_{24} is OH ;

X is $\text{C}-R_{33}$;

R_{31} and R_{32} are independently selected from halogen;

R_{33} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-\text{S}(O)_n\text{CF}_3$, and $-\text{SF}_6$;

r is selected from the group consisting of 0, 1, and 2; and

m is selected from the group consisting of 1 and 2.

3. A compound according to claim 2, wherein R_{23} is CF_3 .

4. The compound according to claim 2, which is 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole.

23

5. The compound according to claim 2, which is 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole.

6. A composition comprising a parasitically effective, substantially non-emetic amount of a compound of formula (I) as defined in claim 1, or a veterinarily acceptable salt thereof, and a veterinarily acceptable carrier therefor.


7. A composition comprising a parasitically effective, substantially non-emetic amount of a compound as defined in claim 2, and a veterinarily acceptable carrier therefor.

8. A composition comprising a parasitically effective, substantially non-emetic amount of a compound as defined in claim 3, and a veterinarily acceptable carrier therefor.

9. A composition comprising a parasitically effective, substantially non-emetic amount of a compound as defined in claim 4, and a veterinarily acceptable carrier therefor.

10. A composition comprising a parasitically effective substantially non-emetic amount of a compound as defined in claim 5, and a veterinarily acceptable carrier therefor.

11. A compound having the formula (II):



wherein:

R_{201} is cyano, $C(=S)NH_2$, $C(=NOH)NH_2$ or $C(=NNH_2)NH_2$;

R_{202} is $S(O)_m R_{203}$;

R_{203} is alkyl or haloalkyl;

R_{204} is OH, $HC(O)O-$, $R_{205}C(O)O-$, $R_{205}OC(O)O-$, $R_{205}R_{206}N-C(O)-O-$ or $R_{205}S(O)_n C(O)O-$;

R_{205} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, heteraryl optionally substituted, arylalkyl optionally substituted, heterarylalkyl optionally substituted, C_2-C_6 alkenyl or C_2-C_6 alkynyl;

or two groups R_{205} form together with the nitrogen to which they are attached a 3 to 7 membered ring which optionally has one or more additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;

X is C— R_{207} ;

R_{207} and R_{208} are independently selected from the group consisting of halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;

R_{209} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-S(O)_m CF_3$ and SF_5 ;

m is selected from the group consisting of 1 and 2; and


r is selected from the group consisting of 0, 1 and 2;

or a veterinarily acceptable salt thereof;

provided that when R_{201} is cyano, then R_{204} is not $R_{205}R_{206}N-C(O)-O-$.

24

12. A compound having the formula (II):



(II)

wherein:

R_{21} is cyano;

R_{22} is $S(O)_m R_{223}$;

R_{223} is alkyl or haloalkyl;

R_{24} is OH, $HC(O)O-$, $R_{225}C(O)O-$, $R_{225}OC(O)O-$ or $R_{225}S(O)_n C(O)O-$;

R_{225} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, heteraryl optionally substituted, arylalkyl optionally substituted, heterarylalkyl optionally substituted, C_2-C_6 alkenyl or C_2-C_6 alkynyl;

or two groups R_{225} form together with the nitrogen to which they are attached a 3 to 7 membered ring which optionally has one or more additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;

X is C— R_{227} ;

R_{227} and R_{228} are independently selected from the group consisting of halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;


R_{229} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-S(O)_m CF_3$ and SF_5 ;

m is selected from the group consisting of 1 and 2; and

r is selected from the group consisting of 0, 1 and 2;

or a veterinarily acceptable salt thereof.

13. A compound having the formula (II):



(II)

wherein:

R_{21} is $C(=S)NH_2$, $C(=NOH)NH_2$ or $C(=NNH_2)NH_2$;

R_{22} is $S(O)_m R_{223}$;

R_{223} is alkyl or haloalkyl;

R_{24} is OH, $HC(O)O-$, $R_{225}C(O)O-$, $R_{225}OC(O)O-$ or $R_{225}S(O)_n C(O)O-$ or $R_{225}S(O)_n C(O)O-$;

R_{225} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylami-

217
244

25

noalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted, C₂-C₆ alkenyl or C₂-C₆ alkynyl;

or two groups R₂₃ form together with the nitrogen to which they are attached a 3 to 7 membered ring which optionally has one or more additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;

X is C—R₃₂;

R₃₁ and R₃₂ are independently selected from the group consisting of halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂;

R₃₃ is selected from the group consisting of halogen, haloalkyl, haloalkoxy, —S(O), CF₃ and SF₅;

m is selected from the group consisting of 0, 1 and 2; and

r is selected from the group consisting of 0, 1 and 2;


or a veterinarily acceptable salt thereof.

14. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound of formula (II) as defined in claim 11, or a veterinarily acceptable salt thereof, and a veterinarily acceptable carrier therefor.

15. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound as defined in claim 12, and a veterinarily acceptable carrier therefor.

16. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound as defined in claim 13, and a veterinarily acceptable carrier therefor.

17. A compound according to claim 1, having the formula (II):



wherein:

R₂₁ is cyano, C(=S)NH₂, C(=NOH)NH₂ or C(=NNH₂)NH₂;

R₂₂ is S(O)_mR₂₃;

R₂₃ is alkyl or haloalkyl;

R₂₄ is OH, HC(O)O—, R₂₅C(O)O—, R₂₅OC(O)O—, R₂₅R₂₆N—C(O)—O— or R₂₅S(O)_nC(O)O—;

R₂₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, arylalkyl optionally substituted, C₂-C₆ alkenyl or C₂-C₆ alkynyl;

X is C—R₃₂;

R₃₁ and R₃₂ are independently selected from the group consisting of halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂;

R₃₃ is selected from the group consisting of halogen, haloalkyl, haloalkoxy, —S(O), CF₃ and SF₅;

r is selected from the group consisting of 0, 1 and 2; and when R₂₁ is cyano, m is selected from the group consisting of 1 and 2, or


when R₂₁ is other than cyano, m is selected from the group consisting of 0, 1 and 2;

or a veterinarily acceptable salt thereof;

26

provided that when R₂₁ is cyano, then R₂₄ is not R₂₅R₂₆N—C(O)—O—.

18. A compound according to claim 11, having the formula (II):



(II)

wherein:

R₂₁ is cyano, C(=S)NH₂, C(=NOH)NH₂ or C(=NNH₂)NH₂;

R₂₂ is S(O)_mR₂₃;

R₂₃ is alkyl or haloalkyl;

R₂₄ is OH, HC(O)O—, R₂₅C(O)O—, R₂₅OC(O)O—, R₂₅R₂₆N—C(O)—O— or R₂₅S(O)_nC(O)O—;

R₂₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, arylalkyl optionally substituted, C₂-C₆ alkenyl or C₂-C₆ alkynyl;

X is C—R₃₂;

R₃₁ and R₃₂ are independently selected from the group consisting of halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂;


R₃₃ is selected from the group consisting of halogen, haloalkyl, haloalkoxy, —S(O), CF₃ and SF₅;

m is selected from the group consisting of 1 and 2; and

r is selected from the group consisting of 0, 1 and 2; or a veterinarily acceptable salt thereof;

provided that when R₂₁ is cyano, then R₂₄ is not R₂₅R₂₆N—C(O)—O—.

19. A compound according to claim 12, having the formula (II):



(II)

wherein:

R₂₁ is cyano;

R₂₂ is S(O)_mR₂₃;

R₂₃ is alkyl or haloalkyl;

R₂₄ is OH, HC(O)O—, R₂₅C(O)O—, R₂₅OC(O)O— or R₂₅S(O)_nC(O)O—;

R₂₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylami-

27

noalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, arylalkyl optionally substituted, C_2-C_6 alkenyl or C_2-C_6 alkynyl;

X is $C-R_{32}$;


R_{31} and R_{32} are independently selected from the group consisting of halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;

R_{33} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-S(O)_mCF_3$ and SF_5 ;

m is selected from the group consisting of 1 and 2; and

r is selected from the group consisting of 0, 1 and 2; or a veterinarily acceptable salt thereof.

20. A compound according to claim 13, having the formula (II):



wherein:

R_{21} is $C(=S)NH_2$, $C(=NOH)NH_2$ or $C(=NNH_2)NH_2$;

R_{22} is $S(O)_mR_{23}$;

R_{23} is alkyl or haloalkyl;

R_{24} is OH, $HC(O)O-$, $R_{25}C(O)O-$, $R_{26}OC(O)O-$,

$R_{27}R_{28}N-C(O)-O-$ or $R_{29}S(O)_mC(O)O-$;

R_{25} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, arylalkyl optionally substituted, C_2-C_6 alkenyl or C_2-C_6 alkynyl;

X is $C-R_{32}$;


R_{31} and R_{32} are independently selected from the group consisting of halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;

R_{33} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-S(O)_mCF_3$ and SF_5 ;

m is selected from the group consisting of 0, 1 and 2; and

r is selected from the group consisting of 0, 1 and 2; or a veterinarily acceptable salt thereof.

21. A compound according to claim 1, having the formula (II):



28

wherein:

R_{21} is cyano, $C(=S)NH_2$, $C(=NOH)NH_2$ or $C(=NNH_2)NH_2$;

R_{22} is $S(O)_mR_{23}$;

R_{23} is alkyl or haloalkyl;

R_{24} is OH;

R_{25} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, arylalkyl optionally substituted, C_2-C_6 alkenyl or C_2-C_6 alkynyl;

X is $C-R_{32}$;

R_{31} and R_{32} are independently selected from the group consisting of halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;


R_{33} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-S(O)_mCF_3$ and SF_5 ;

r is selected from the group consisting of 0, 1 and 2; and when R_{21} is cyano, m is selected from the group consisting of 1 and 2, or

when R_{21} is other than cyano, m is selected from the group consisting of 0, 1 and 2;

or a veterinarily acceptable salt thereof.

22. A compound according to claim 11, having the formula (II):



wherein:

R_{21} is cyano, $C(=S)NH_2$, $C(=NOH)NH_2$ or $C(=NNH_2)NH_2$;

R_{22} is $S(O)_mR_{23}$;

R_{23} is alkyl or haloalkyl;

R_{24} is OH;

R_{25} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, arylalkyl optionally substituted, C_2-C_6 alkenyl or C_2-C_6 alkynyl;

X is $C-R_{32}$;


R_{31} and R_{32} are independently selected from the group consisting of halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;

R_{33} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-S(O)_mCF_3$ and SF_5 ;

m is selected from the group consisting of 1 and 2; and

r is selected from the group consisting of 0, 1 and 2; or a veterinarily acceptable salt thereof.


23. A compound according to claim 12, having the formula (II):



wherein:

- R_{21} is cyano;
 R_{22} is $S(O)_m R_{23}$;
 R_{23} is alkyl or haloalkyl;
 R_{24} is OH;
 R_{25} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, arylalkyl optionally substituted, C_2-C_6 alkenyl or C_2-C_6 alkynyl;
 X is $C-R_{33}$;
 R_{31} and R_{32} are independently selected from the group consisting of halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;
 R_{33} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-S(O)_r CF_3$ and SF_5 ;
 m is selected from the group consisting of 0, 1 and 2; and
 r is selected from the group consisting of 0, 1 and 2; or a veterinarily acceptable salt thereof.

24. A compound according to claim 13, having the formula (II):



wherein:

- R_{21} is $C(=S)NH_2$, $C(=NOH)NH_2$ or $C(=NNH_2)NH_2$;
 R_{22} is $S(O)_m R_{23}$;
 R_{23} is alkyl or haloalkyl;
 R_{24} is OH;
 R_{25} is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, arylalkyl optionally substituted, C_2-C_6 alkenyl or C_2-C_6 alkynyl;
 X is $C-R_{33}$;
 R_{31} and R_{32} are independently selected from the group consisting of halogen, hydrogen, CN, C_1-C_3 alkyl and NO_2 ;
 R_{33} is selected from the group consisting of halogen, haloalkyl, haloalkoxy, $-S(O)_r CF_3$ and SF_5 ;
 m is selected from the group consisting of 0, 1 and 2; and
 r is selected from the group consisting of 0, 1 and 2; or a veterinarily acceptable salt thereof.
25. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound of formula (II) as defined in claim 17, or a veterinarily acceptable salt thereof, and a veterinarily acceptable carrier therefor.
26. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound as defined in claim 18, and a veterinarily acceptable carrier therefor.
27. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound as defined in claim 19, and a veterinarily acceptable carrier therefor.
28. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound as defined in claim 20, and a veterinarily acceptable carrier therefor.
29. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound of formula (II) as defined in claim 21, or a veterinarily acceptable salt thereof, and a veterinarily acceptable carrier therefor.
30. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound as defined in claim 22, and a veterinarily acceptable carrier therefor.
31. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound of formula (II) as defined in claim 23, or a veterinarily acceptable salt thereof, and a veterinarily acceptable carrier therefor.
32. A composition comprising a parasitocidally effective, substantially non-emetic amount of a compound as defined in claim 24, and a veterinarily acceptable carrier therefor.

* * * * *